Low-dose cytosine arabinoside for treating hypocellular acute leukemia in the elderly.
Ten previously untreated elderly patients with hypocellular acute leukemia received a low dose of cytosine arabinoside (Ara-C), 10 mg/m2 injected subcutaneously every 12 hours for 14-28 days. Six patients achieved a complete remission (CR) for periods ranging for 6-23 months (median 8.5 months) and the others had a partial remission (PR). Relapse has occurred in three patients to date. The median survival ranged from 10-24 months (median 14.5 months). Only two of the six patients, in whom bone marrow biopsy was performed at CR, had a normal cellularity. This change, however, did not appear to be a significant prognostic factor in those patients. In seven patients who achieved a CR or PR low-dose Ara-C was administrated as maintenance therapy at the same low dose for 10 days each month. Treatment was well tolerated in all patients despite for myelosuppression. There were no drug-related deaths. These observations suggest that low-dose Ara-C is effective in treating elderly patients with hypocellular acute leukemia.
Kanamori
H
H
Department of Hematology/Chemotherapy, Kanagawa Cancer Center, Japan.
Maruta
A
A
Miyashita
H
H
Harano
H
H
Fukawa
H
H
Matsuzaki
M
M
Motomura
S
S
Mohri
H
H
Kodama
F
F
Okubo
T
T
D000208:Acute Disease; D000367:Age Factors; D000368:Aged; D003561:Cytarabine / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D003561:Cytarabine